Network origin in Sharon Grimster first degree
Entity | Entity type | Industry | |
---|---|---|---|
Public Company | Pharmaceuticals: Major | 10 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Sharon Grimster via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
ALLERGAN, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
BECTON, DICKINSON AND COMPANY | Medical Specialties | Chief Tech/Sci/R&D Officer | |
Roche Pharmaceuticals, Inc.
Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Roche Pharmaceuticals provides research and development services in the fields of pharmaceuticals and diagnostics. It also provides diagnostics and drugs for cancer and transplantation. The company is headquartered in Nutley, NJ. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
SAREUM HOLDINGS PLC | Miscellaneous | Chairman Director/Board Member | |
Antisoma Research Ltd. | Corporate Officer/Principal | ||
EUSA Pharma, Inc.
EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | Pharmaceuticals: Major | Founder | |
Lux Biosciences, Inc.
Lux Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Lux Biosciences, Inc. provides therapies for treatment of ophthalmic diseases. It develops and commercializes medications for ophthalmic diseases. The company was founded by Ulrich M. Grau, Eddy Anglade, Clarke A. Atwell and Sidney L. Weiss in 2006 and is headquartered in Jersey City, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Danube Pharmaceuticals, Inc.
Danube Pharmaceuticals, Inc. BiotechnologyHealth Technology Danube Pharmaceuticals, Inc. provides bio pharmaceutical services. It engages in the discovery and development of therapies and devices for ophthalmology. The firm's products include DNB-001, a small molecule for the treatment of glaucoma. The company was founded in 2006 and is headquartered in New York, NY. | Biotechnology | Chief Tech/Sci/R&D Officer | |
UNILIFE CORP | Medical Specialties | Chief Tech/Sci/R&D Officer | |
GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
University of Oxford | College/University | Undergraduate Degree | |
Imperial College London | College/University | Undergraduate Degree | |
Alcon Laboratories, Inc.
Alcon Laboratories, Inc. Medical SpecialtiesHealth Technology Alcon Laboratories, Inc. develops and manufactures ophthalmic pharmaceutical products. The firm offers over-the-counter eye care products, medical devices, equipment, ophthalmic drugs, surgical instruments, needles, and sutures for microsurgery and disposable drapes. The company was founded by Robert Alexander and William Conner in 1945 and is headquartered in Fort Worth, TX. | Medical Specialties | Chief Tech/Sci/R&D Officer | |
University of Cambridge | College/University | Doctorate Degree | |
Neurotech Pharmaceuticals, Inc. (United States)
Neurotech Pharmaceuticals, Inc. (United States) Pharmaceuticals: MajorHealth Technology Neurotech Pharmaceuticals, Inc. designs and develops therapeutic systems for retinal diseases. The company was founded in 1995 and is headquartered in Cumberland, RI. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
RRG Group Ltd.
RRG Group Ltd. Specialty StoresRetail Trade RRG Group Ltd. markets and sells new and used automobiles and light trucks. The firm offers parts and accessories, motoring services for businesses, after sale services, and accident repair services including color coding, body kit, spoiler, air conditioning, valeting and cleaning, and supaguard paint protection. The company was founded by Michael Smyth in June 1967 and is headquartered in Salford, the United Kingdom. | Specialty Stores | Director/Board Member | |
Ipsen Ltd.
Ipsen Ltd. Pharmaceuticals: MajorHealth Technology Ipsen Ltd. develops and markets medicinal products. The firm provides Decapepty, Disport, Hexvix, Increlex and Somatuline. The company is headquartered in Slough, the United Kingdom. | Pharmaceuticals: Major | General Counsel | |
Kyowa Kirin International Plc
Kyowa Kirin International Plc Pharmaceuticals: MajorHealth Technology Kyowa Kirin International Plc is a specialty pharmaceutical company, which engages in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major markets. It offers Sancuso, a prescription medicine used to prevent nausea and vomiting in people receiving some types of chemotherapy treatment and Abstral, a medicine used in the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. The company was founded in 1995 and is headquartered in Galashiels, the United Kingdom. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
University of Michigan | College/University | Doctorate Degree | |
Cranfield University | College/University | Masters Business Admin | |
ZEALAND PHARMA A/S | Pharmaceuticals: Major | Director/Board Member | |
WEIFA ASA | Pharmaceuticals: Major | Corporate Officer/Principal | |
AVACTA GROUP PLC | Miscellaneous Commercial Services | Director/Board Member | |
University of Hertfordshire | College/University | Undergraduate Degree | |
The European Molecular Biology Laboratory | College/University | Corporate Officer/Principal | |
IVERIC BIO, INC. | Pharmaceuticals: Generic | Chief Tech/Sci/R&D Officer | |
European Molecular Biology Organization | Corporate Officer/Principal | ||
Ysios Capital Partners SGEIC SA
Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona. | Investment Managers | Private Equity Investor | |
The University of Law Ltd. | College/University | Graduate Degree | |
REDX PHARMA PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
Iksuda Therapeutics Ltd.
Iksuda Therapeutics Ltd. BiotechnologyHealth Technology Iksuda Therapeutics Ltd. operates as a biotechnology company which specializes in the development of next generation biotherapeutics. It creates new generation biological therapeutics through advanced glycosylation and conjugation technologies. The company has core expertise in protein/peptide fictionalization and glycosylation technologies, imparting improved pharmacokinetic properties to a broader range of biological therapeutics. It was founded by David John Simpson and Andrew Watts on November 21, 2007 and is headquartered in Newcastle upon Tyne, the United Kingdom. | Biotechnology | Director/Board Member | |
Ossianix, Inc.
Ossianix, Inc. Pharmaceuticals: GenericHealth Technology Ossianix, Inc. develops single domain antibodies. It develops biotherapeutic products using the versatile single domain VNAR antibody from the shark and also developed highly innovative approaches to target specific cells and tissues such as the brain via the blood brain barrier and peripheral nerve via the neuromuscular junction. The company was founded by Frank S. Walshin, J. Lynn Rutkowski and Corey S. Goodman in 2011 and is headquartered in Philadelphia, PA. | Pharmaceuticals: Generic | Chairman | |
CLEARSIDE BIOMEDICAL, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Phosphate Therapeutics Ltd.
Phosphate Therapeutics Ltd. BiotechnologyHealth Technology Phosphate Therapeutics Ltd. provides research and experimental development on biotechnology. It engages in development of drug named PT20 to cure high phosphate levels in blood. The company was founded in 2011 and is headquartered in Gateshead Quays, the United Kingdom. | Biotechnology | Chief Tech/Sci/R&D Officer | |
ADVERUM BIOTECHNOLOGIES, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Voisin Consulting, Inc.
Voisin Consulting, Inc. Miscellaneous Commercial ServicesCommercial Services Voisin Consulting, Inc. provides product development consulting services. It guides biotechnology, pharmaceutical and medical technology manufacturers throughout product development and commercialization. The company was founded by Emanuelle M. Viosin in 1997 and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Director/Board Member | |
SHIELD THERAPEUTICS PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
Gammadelta Therapeutics Ltd.
Gammadelta Therapeutics Ltd. BiotechnologyHealth Technology Gammadelta Therapeutics Ltd. is developing the potential of gamma delta (?d) cells to create improved immunotherapy of cancer and other serious diseases. The company was founded by Raj Mehta in 2016 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member | |
Sensia SL | Director/Board Member | ||
Avacta Life Sciences Ltd.
Avacta Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology Avacta Life Sciences Ltd. provides powerful reagents for research and diagnostics. The company is headquartered in Wetherby, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Aquanima Management Consulting
Aquanima Management Consulting Miscellaneous Commercial ServicesCommercial Services Aquanima Management Consulting provides management consulting services. The private company is based in Madrid, Spain. | Miscellaneous Commercial Services | Director/Board Member | |
The Club Cricket Organisation Ltd. | Director/Board Member | ||
Ossianix Uk Ltd. | Director/Board Member | ||
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Biotechnology | Director/Board Member |
Statistics
International
United Kingdom | 25 |
United States | 16 |
Spain | 4 |
Switzerland | 4 |
Germany | 3 |
Sectoral
Health Technology | 30 |
Consumer Services | 9 |
Commercial Services | 5 |
Finance | 3 |
Miscellaneous | 2 |
Operational
Director/Board Member | 39 |
Corporate Officer/Principal | 26 |
Chairman | 18 |
Chief Tech/Sci/R&D Officer | 16 |
Independent Dir/Board Member | 15 |
Most connected contacts
Insiders | |
---|---|
Bryan Geoffrey Morton | 22 |
Paul Harper | 20 |
Michael Owen | 20 |
Mark James Docherty | 14 |
Claudia D'Augusta | 12 |
Richard Beckman | 12 |
Julian Howell | 8 |
Nicholas Adams | 7 |
Shaun Stapleton | 5 |
Suzanne Hancock | 2 |
- Stock Market
- Insiders
- Sharon Grimster
- Company connections